(CPRX) Catalyst Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US14888U1016

CPRX EPS (Earnings per Share)

This chart shows the EPS (Earnings per Share) of CPRX over the last 5 years for every Quarter.

CPRX Revenue

This chart shows the Revenue of CPRX over the last 5 years for every Quarter.

CPRX: Firdapse, Fycompa, Ruzurgi, AGAMREE, Sabril

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company specializing in rare disease treatments in the US. The company has a diverse portfolio of medications, including Firdapse for Lambert-Eaton myasthenic syndrome (LEMS), Fycompa for focal onset seizures and tonic-clonic seizures, Ruzurgi for pediatric LEMS, and AGAMREE, a corticosteroid for Duchenne muscular dystrophy.

The companys strategic partnerships, such as its license agreements with BioMarin Pharmaceutical Inc. and collaboration with Endo Ventures Limited, enhance its product offerings and commercialization capabilities. With a strong focus on rare disease treatments, Catalyst Pharmaceuticals has established itself as a key player in the biotechnology industry.

Analyzing the companys , we observe a stable short-term trend, with the stock price hovering around its 20-day Simple Moving Average (SMA20) of $24.87. The 50-day SMA ($23.86) and 200-day SMA ($22.23) indicate a longer-term uptrend. The Average True Range (ATR) of 0.87, representing a 3.59% daily price movement, suggests moderate volatility.

From a fundamental perspective, Catalyst Pharmaceuticals boasts a market capitalization of $3.044 billion, with a price-to-earnings (P/E) ratio of 15.86 and a forward P/E of 13.46. The companys Return on Equity (RoE) stands at 28.28%, indicating strong profitability.

Combining technical and fundamental insights, we forecast that CPRX will continue its upward trend, driven by its robust product pipeline and strategic partnerships. As the stock price is currently near its 20-day SMA, we anticipate a potential breakout above $26, targeting the 52-week high of $26.31. Conversely, a decline below $23.86 may signal a correction, with support around $22.23. Our forecast is based on the assumption that the companys rare disease focus and partnerships will continue to drive growth, supported by a favorable industry trend.

To validate this forecast, we recommend closely monitoring Catalyst Pharmaceuticals future earnings reports, product approvals, and industry developments, as these factors will significantly impact the stocks performance. A thorough analysis of the companys financials, management team, and competitive landscape will also be essential in determining the stocks long-term potential.

Additional Sources for CPRX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

CPRX Stock Overview

Market Cap in USD 3,045m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2006-11-08

CPRX Stock Ratings

Growth Rating 91.2
Fundamental 92.8
Dividend Rating 0.0
Rel. Strength 70.6
Analysts 4.88 of 5
Fair Price Momentum 28.57 USD
Fair Price DCF 35.54 USD

CPRX Dividends

Currently no dividends paid

CPRX Growth Ratios

Growth Correlation 3m 38.1%
Growth Correlation 12m 89.1%
Growth Correlation 5y 93.4%
CAGR 5y 38.42%
CAGR/Max DD 5y 0.85
Sharpe Ratio 12m 0.33
Alpha 45.24
Beta 0.837
Volatility 47.83%
Current Volume 1123.4k
Average Volume 20d 1116.2k
What is the price of CPRX shares?
As of June 18, 2025, the stock is trading at USD 23.22 with a total of 1,123,446 shares traded.
Over the past week, the price has changed by -11.74%, over one month by -5.72%, over three months by +6.46% and over the past year by +54.80%.
Is Catalyst Pharmaceuticals a good stock to buy?
Yes, based on ValueRay´s Fundamental Analyses, Catalyst Pharmaceuticals (NASDAQ:CPRX) is currently (June 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 92.81 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CPRX is around 28.57 USD . This means that CPRX is currently undervalued and has a potential upside of +23.04% (Margin of Safety).
Is CPRX a buy, sell or hold?
Catalyst Pharmaceuticals has received a consensus analysts rating of 4.88. Therefor, it is recommend to buy CPRX.
  • Strong Buy: 7
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecasts for CPRX share price target?
According to our own proprietary Forecast Model, CPRX Catalyst Pharmaceuticals will be worth about 32.1 in June 2026. The stock is currently trading at 23.22. This means that the stock has a potential upside of +38.37%.
Issuer Target Up/Down from current
Wallstreet Target Price 34 46.4%
Analysts Target Price 34 46.4%
ValueRay Target Price 32.1 38.4%